Skip to main content
  • More from ADA
    • Diabetes Care
    • Clinical Diabetes
    • Diabetes Spectrum
    • ADA Standards of Medical Care in Diabetes
    • ADA Scientific Sessions Abstracts
    • BMJ Open Diabetes Research & Care
  • Subscribe
  • Log in
  • My Cart
  • Follow ada on Twitter
  • RSS
  • Visit ada on Facebook
Diabetes

Advanced Search

Main menu

  • Home
  • Current
    • Current Issue
    • Online Ahead of Print
    • ADA Scientific Sessions Abstracts
  • Browse
    • By Topic
    • Issue Archive
    • Saved Searches
    • ADA Scientific Sessions Abstracts
    • Diabetes COVID-19 Article Collection
    • Diabetes Symposium 2020
  • Info
    • About the Journal
    • About the Editors
    • ADA Journal Policies
    • Instructions for Authors
    • Guidance for Reviewers
  • Reprints/Reuse
  • Advertising
  • Subscriptions
    • Individual Subscriptions
    • Institutional Subscriptions and Site Licenses
    • Access Institutional Usage Reports
    • Purchase Single Issues
  • Alerts
    • E­mail Alerts
    • RSS Feeds
  • Podcasts
    • Diabetes Core Update
    • Special Podcast Series: Therapeutic Inertia
    • Special Podcast Series: Influenza Podcasts
    • Special Podcast Series: SGLT2 Inhibitors
    • Special Podcast Series: COVID-19
  • Submit
    • Submit a Manuscript
    • Submit Cover Art
    • ADA Journal Policies
    • Instructions for Authors
    • ADA Peer Review
  • More from ADA
    • Diabetes Care
    • Clinical Diabetes
    • Diabetes Spectrum
    • ADA Standards of Medical Care in Diabetes
    • ADA Scientific Sessions Abstracts
    • BMJ Open Diabetes Research & Care

User menu

  • Subscribe
  • Log in
  • My Cart

Search

  • Advanced search
Diabetes
  • Home
  • Current
    • Current Issue
    • Online Ahead of Print
    • ADA Scientific Sessions Abstracts
  • Browse
    • By Topic
    • Issue Archive
    • Saved Searches
    • ADA Scientific Sessions Abstracts
    • Diabetes COVID-19 Article Collection
    • Diabetes Symposium 2020
  • Info
    • About the Journal
    • About the Editors
    • ADA Journal Policies
    • Instructions for Authors
    • Guidance for Reviewers
  • Reprints/Reuse
  • Advertising
  • Subscriptions
    • Individual Subscriptions
    • Institutional Subscriptions and Site Licenses
    • Access Institutional Usage Reports
    • Purchase Single Issues
  • Alerts
    • E­mail Alerts
    • RSS Feeds
  • Podcasts
    • Diabetes Core Update
    • Special Podcast Series: Therapeutic Inertia
    • Special Podcast Series: Influenza Podcasts
    • Special Podcast Series: SGLT2 Inhibitors
    • Special Podcast Series: COVID-19
  • Submit
    • Submit a Manuscript
    • Submit Cover Art
    • ADA Journal Policies
    • Instructions for Authors
    • ADA Peer Review
Complications

Derivative of Bardoxolone Methyl, dh404, in an Inverse Dose-Dependent Manner Lessens Diabetes-Associated Atherosclerosis and Improves Diabetic Kidney Disease

  1. Sih Min Tan1,
  2. Arpeeta Sharma1,
  3. Nada Stefanovic1,
  4. Derek Y.C. Yuen1,
  5. Tom C. Karagiannis2,
  6. Colin Meyer3,
  7. Keith W. Ward3,
  8. Mark E. Cooper1 and
  9. Judy B. de Haan1⇑
  1. 1Oxidative Stress Laboratory, Diabetic Complications Division, Baker IDI Heart and Diabetes Institute, Melbourne, Australia
  2. 2Epigenomic Medicine, Baker IDI Heart and Diabetes Institute, Melbourne, Australia
  3. 3Reata Pharmaceuticals, Inc., Irving, TX
  1. Corresponding author: Judy B. de Haan, judy.dehaan{at}bakeridi.edu.au.
Diabetes 2014 Sep; 63(9): 3091-3103. https://doi.org/10.2337/db13-1743
PreviousNext
  • Article
  • Figures & Tables
  • Suppl Material
  • Info & Metrics
  • PDF
Loading

Article Figures & Tables

Figures

  • Tables
  • Figure 1
    • Download figure
    • Open in new tab
    • Download powerpoint
    Figure 1

    Diabetes-associated lesion formation in the aorta and aortic sinus is attenuated by dh404 after 18 weeks of treatment. Aortas were stained with Sudan IV Herxheimer’s solution, and plaques were stained red (A). Treatment with dh404 at 3 and 10 mg/kg/day resulted in an attenuation of total plaque formation in the aortas of diabetic mice (B), and similar effects were found in the aortic arch (C), thoracic (D), and abdominal regions (E). F: Cryosections of aortic sinus were stained with Oil Red O to detect plaque formation after 18 weeks of dh404 treatment. G: At 3 and 10 mg/kg/day, plaque formation was significantly attenuated in diabetic mice when compared with their vehicle-treated counterparts. Data are mean ± SEM. **P < 0.01, ***P < 0.001 vs. ND+SO; #P < 0.05, ##P < 0.01 vs. D+SO; ^P < 0.05, ^^P < 0.01 vs. as indicated. Abd, abdominal region; Arch, aortic arch; D, diabetic mice; dh-3, -10, and -20, dh404 at 3, 10, or 20 mg/kg/day; ND, nondiabetic mice; Thor, thoracic.

  • Figure 2
    • Download figure
    • Open in new tab
    • Download powerpoint
    Figure 2

    Adhesion and inflammatory markers in aorta are reduced by dh404. The gene expression of adhesion and inflammatory markers in the aorta was assessed by qRT-PCR after 5 weeks of treatment (A–F). VCAM-1 protein expression was examined using immunohistochemistry in aortic plaque (G), and the quantitation is shown in H. Data are mean ± SEM. For qRT-PCR analysis, n = 6–10 (MCP-1), 7–10 (TNF-α), and 8–10 (CD36, ICAM-1, p65, and VCAM-1) aortas/group. *P < 0.05, **P < 0.01 vs. ND+SO; #P < 0.05, ##P < 0.01 vs. D+SO. A.U., arbitrary units; D, diabetic mice dh-3, -10, and -20, dh404 at 3, 10, or 20 mg/kg/day; ND, nondiabetic mice.

  • Figure 3
    • Download figure
    • Open in new tab
    • Download powerpoint
    Figure 3

    Diabetes-associated oxidative stress is attenuated by dh404 after 18 weeks of treatment. Oxidative stress was assessed by urine levels of 8-isoprostane (A) and 8-OHdG (B) and plasma levels of dROMs (C). All of these markers were attenuated in the diabetic mice by dh404. Nitrotyrosine immunostaining revealed that diabetes was associated with an increase in nitrotyrosine protein expression, and this was attenuated by dh404 at all doses (D and E). Data are mean ± SEM. *P < 0.05, **P < 0.01, ***P < 0.001 vs. ND+SO; #P < 0.05, ##P < 0.01, ###P < 0.001 vs. D+SO. D, diabetic mice; dh-3, -10, and -20, dh404 at 3, 10, or 20 mg/kg/day; ND, nondiabetic mice; U.Carr, Carratelli units.

  • Figure 4
    • Download figure
    • Open in new tab
    • Download powerpoint
    Figure 4

    dh404 increases antioxidant as well as inflammatory gene expression after 5 weeks of treatment, improves kidney function, and attenuates glomerulosclerosis and tubulointerstitial injury after 18 weeks of treatment. The gene expression of antioxidants NQO1, GSH-S transferase, and GPx1 was increased in the kidney cortex by dh404 after 5 weeks of treatment (A). However, inflammatory genes such as MCP-1 and NF-κB were also upregulated by dh404 (B). Diabetes-associated increase in urinary albumin-to-creatinine ratio (UACR) was reduced by dh404 (C); however, dh404 treatment had no effect on plasma cystatin C levels (D). Glomerulosclerosis was assessed by measuring PAS-stained area per glomerulus (indicative of mesangial expansion) and also scored for GSI. Photomicrographs of representative glomeruli are shown in E. Treatment of dh404 at 3 mg/kg/day for 18 weeks significantly attenuated mesangial expansion (F) and GSI (G). The percentage of tubulointerstitial injury was determined from PAS-stained sections by point-counting and is shown in H. Data are mean ± SEM. *P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001 vs. ND+SO; #P < 0.05, ##P < 0.01, ###P < 0.001 vs. D+SO. A.U., arbitrary units; D, diabetic mice; dh-3, -10, and -20, dh404 at 3, 10, or 20 mg/kg/day; gcs, glomerular cross-sectional area; ND, nondiabetic mice.

  • Figure 5
    • Download figure
    • Open in new tab
    • Download powerpoint
    Figure 5

    In vitro analysis of Nrf2-responsive antioxidant genes in NRK cells after dh404 treatment. NRK cells were treated with DMSO, dh404, TGF-β+DMSO, or TGF-β+dh404 for 72 h as detailed in the Research Design and Methods. Gene-expression profiles of HO-1, NQO1, GSH-S transferase, GPx1, GPx2, and GPx3 are shown in A. dh404, in most cases, caused dose-dependent increases in the gene expression of most antioxidants investigated either in the presence or absence of TGF-β treatment. Protein levels for HO-1 and GPx1 after treatment of NRK cells with 0.5 µmol dh404 for 72 h are shown in B. Data are mean ± SEM from five separate experiments for quantitative PCR analyses (n = 5) and three separate experiments for Western blot analysis (n = 3). For the quantitative PCR studies, data were normalized to controls (given arbitrary value of 1) as fold change and then averaged over replicate five experiments. Lane 1, DMSO; lane 2, dh404; lane 3, TGF-β+DMSO; lane 4, TGF-β+dh404. *P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001 vs. CTL+DMSO; #P < 0.05, ##P < 0.01, ###P < 0.001, ####P < 0.0001 vs. TGF-β+DMSO; ^P < 0.05 CTL+dh404 vs. TGF-β+dh404. A.U., arbitrary units; CTL, control.

  • Figure 6
    • Download figure
    • Open in new tab
    • Download powerpoint
    Figure 6

    In vitro analysis of Nrf2-responsive anti-inflammatory and fibrosis genes in NRK cells after dh404 treatment. NRK cells were treated with either DMSO, dh404, TGF-β+DMSO, or TGF-β+dh404 for 72 h as detailed in the Research Design and Methods. Gene expression profiles of IL-6, MCP-1, and the p65 subunit of NF-κB are shown in A. Gene expression of fibronectin (FN), collagen I (Col I), and collagen IV (Col IV) are shown in B. Despite decreases in IL-6 expression with increasing doses of dh404, MCP-1 showed a significant increase in gene expression at higher doses of dh404. Collagen I and IV as well as FN gene expression were significantly attenuated by dh404. FN protein levels, shown in C, were significantly reduced after 0.5 µmol dh404 treatment. Data are mean ± SEM from five separate experiments for quantitative PCR analyses (n = 5) and three separate experiments for Western blot analysis (n = 3). For the quantitative PCR studies, data were normalized to control subjects (given arbitrary value of 1) as fold change and then averaged over replicate five experiments. *P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001 vs. CTL+DMSO; #P < 0.05, ##P < 0.01, ###P < 0.001, ####P < 0.0001 vs. TGF-β+DMSO; ^^^P < 0.001 CTL+dh404 vs. TGF-β+dh404. Lane 1, DMSO; lane 2, dh404; lane 3, TGF-β+DMSO; lane 4, TGF-β+dh404. A.U., arbitrary units; CTL, control.

Tables

  • Figures
  • Table 1

    Basic characteristics of nondiabetic and diabetic ApoE−/− mice treated with vehicle (SO) or dh404 at conclusion of 18-week study

    ND+SO (n = 9)ND+dh-20 (n = 8)D+SO (n = 5)D+dh-3 (n = 7)D+dh-10 (n = 8)D+dh-20 (n = 9)
    BW, g30.7 ± 0.931.1 ± 0.621.8 ± 0.4***27.5 ± 0.7**,###26.8 ± 0.6 ***,###23.0 ± 0.6***
    Right kidney weight/BW, mg/g6.8 ± 0.26.4 ± 0.311.1 ± 0.4***8.4 ± 0.2*,##8.4 ± 0.7**,##9.0 ± 0.6**,##
    Left kidney weight/BW, mg/g6.9 ± 0.16.9 ± 0.310.5 ± 0.3***8.4 ± 0.1#7.7 ± 0.5###9.3 ± 0.7***
    Liver weight/BW, mg/g42.5 ± 1.543.9 ± 1.259.7 ± 1.3**52.1 ± 4.2*59.6 ± 2.0***58.8 ± 3.7***
    Lung weight/BW, mg/g5.8 ± 0.25.9 ± 0.27.5 ± 0.4***6.6 ± 0.26.6 ± 0.27.3 ± 0.2***
    Heart weight/BW, mg/g4.9 ± 0.15.6 ± 0.65.9 ± 0.25.5 ± 0.34.8 ± 0.16.0 ± 0.4
    • Data are presented as mean ± SEM.

    • BW, body weight; D, diabetic; dh-3, -10, and -20, dh404 at 3, 10, and 20 mg/kg/day; ND, nondiabetic.

    • *P < 0.05, **P < 0.01, ***P < 0.001 vs. ND+SO; #P < 0.05, ##P < 0.01, ###P < 0.001 vs. D+SO.

  • Table 2

    Metabolic parameters of nondiabetic and diabetic ApoE−/− mice treated with vehicle (SO) or dh404 at conclusion of 18-week study

    ND+SO (n = 9)ND+dh-20 (n = 8)D+SO (n = 5)D+dh-3 (n = 7)D+dh-10 (n = 8)D+dh-20 (n = 9)
    HbA1c, % 4.3 ± 0.13.5 ± 0.113.2 ± 1.010.4 ± 1.910.6 ± 1.010.5 ± 1.4
    HbA1c, mol/mol23 ± 1.115 ± 1.1121 ± 10.9***90 ± 20.8***92 ± 10.9***91 ± 15.3***
    Blood glucose, mmol/L8.9 ± 0.78.2 ± 0.422.8 ± 2.0***20.7 ± 2.9***23.9 ± 1.6***21.7 ± 2.6***
    Total cholesterol, mmol/L10.5 ± 0.614.0 ± 1.421.9 ± 1.3***14.4 ± 1.5##15.2 ± 1.4##17.6 ± 1.6**,#
    Triglycerides, mmol/L1.9 ± 0.41.3 ± 0.37.3 ± 1.0***4.4 ± 0.8*,#4.0 ± 0.4*,#5.3 ± 0.9**
    HDL, mmol/L2.2 ± 0.13.1 ± 0.3*4.3 ± 0.3***2.7 ± 0.3##3.1 ± 0.3*,#3.2 ± 0.3*,#
    LDL, mmol/L7.5 ± 0.410.4 ± 1.014.4 ± 0.9***9.8 ± 1.1#10.3 ± 1.112.0 ± 1.1**
    Plasma AST, units/L155 ± 34103 ± 17201 ± 82153 ± 42233 ± 74187 ± 72
    Plasma ALT, units/L43 ± 829 ± 1656 ± 1750 ± 20100 ± 3951 ± 33
    Water intake, mL/24 h4.1 ± 0.40.7 ± 0.224.0 ± 1.6***17.1 ± 3.0***19.4 ± 2.2***16.6 ± 3.9***
    Food intake, g/24 h2.4 ± 0.23.2 ± 0.25.2 ± 0.4***3.8 ± 0.3*4.4 ± 0.3***4.9 ± 0.5***
    Urinary output, mL/24 h1.0 ± 0.21.9 ± 0.222.5 ± 2.0***13.6 ± 2.7**14.7 ± 2.3**16.7 ± 4.1***
    • Data are presented as mean ± SEM.

    • D, diabetic; dh-3, -10, and -20, dh404 at 3, 10, and 20 mg/kg/day; ND, nondiabetic.

    • *P < 0.05, **P < 0.01, ***P < 0.001 vs. ND+SO; #P < 0.05, ##P < 0.01 vs. D+SO.

PreviousNext
Back to top
Diabetes: 63 (9)

In this Issue

September 2014, 63(9)
  • Table of Contents
  • Table of Contents (PDF)
  • About the Cover
  • Index by Author
  • Masthead (PDF)
Sign up to receive current issue alerts
View Selected Citations (0)
Print
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for your interest in spreading the word about Diabetes.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Derivative of Bardoxolone Methyl, dh404, in an Inverse Dose-Dependent Manner Lessens Diabetes-Associated Atherosclerosis and Improves Diabetic Kidney Disease
(Your Name) has forwarded a page to you from Diabetes
(Your Name) thought you would like to see this page from the Diabetes web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Derivative of Bardoxolone Methyl, dh404, in an Inverse Dose-Dependent Manner Lessens Diabetes-Associated Atherosclerosis and Improves Diabetic Kidney Disease
Sih Min Tan, Arpeeta Sharma, Nada Stefanovic, Derek Y.C. Yuen, Tom C. Karagiannis, Colin Meyer, Keith W. Ward, Mark E. Cooper, Judy B. de Haan
Diabetes Sep 2014, 63 (9) 3091-3103; DOI: 10.2337/db13-1743

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Add to Selected Citations
Share

Derivative of Bardoxolone Methyl, dh404, in an Inverse Dose-Dependent Manner Lessens Diabetes-Associated Atherosclerosis and Improves Diabetic Kidney Disease
Sih Min Tan, Arpeeta Sharma, Nada Stefanovic, Derek Y.C. Yuen, Tom C. Karagiannis, Colin Meyer, Keith W. Ward, Mark E. Cooper, Judy B. de Haan
Diabetes Sep 2014, 63 (9) 3091-3103; DOI: 10.2337/db13-1743
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • Abstract
    • Introduction
    • Research Design and Methods
    • Results
    • Discussion
    • Article Information
    • Footnotes
    • References
  • Figures & Tables
  • Suppl Material
  • Info & Metrics
  • PDF

Related Articles

Cited By...

More in this TOC Section

  • Interphotoreceptor Retinol-Binding Protein Ameliorates Diabetes-Induced Retinal Dysfunction and Neurodegeneration Through Rhodopsin
  • Lung and Kidney ACE2 and TMPRSS2 in Renin-Angiotensin System Blocker–Treated Comorbid Diabetic Mice Mimicking Host Factors That Have Been Linked to Severe COVID-19
  • Specific NLRP3 Inhibition Protects Against Diabetes-Associated Atherosclerosis
Show more Complications

Similar Articles

Navigate

  • Current Issue
  • Online Ahead of Print
  • Scientific Sessions Abstracts
  • Collections
  • Archives
  • Submit
  • Subscribe
  • Email Alerts
  • RSS Feeds

More Information

  • About the Journal
  • Instructions for Authors
  • Journal Policies
  • Reprints and Permissions
  • Advertising
  • Privacy Policy: ADA Journals
  • Copyright Notice/Public Access Policy
  • Contact Us

Other ADA Resources

  • Diabetes Care
  • Clinical Diabetes
  • Diabetes Spectrum
  • Scientific Sessions Abstracts
  • Standards of Medical Care in Diabetes
  • BMJ Open - Diabetes Research & Care
  • Professional Books
  • Diabetes Forecast

 

  • DiabetesJournals.org
  • Diabetes Core Update
  • ADA's DiabetesPro
  • ADA Member Directory
  • Diabetes.org

© 2021 by the American Diabetes Association. Diabetes Print ISSN: 0012-1797, Online ISSN: 1939-327X.